Over the past 12 months, 7 insiders at Karyopharm Therapeutics Inc. filed 21 open-market SEC Form 4 transactions on KPTI: 0 purchases worth $0 and 21 sales worth $333K. Insiders have been net sellers over this period. The most recent filing was on May 14, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| May 14, 26 | Kristin AbateChief Accounting Officer | SELL | 53 | $9.50 | $504 |
| May 14, 26 | Sohanya Roshan ChengEVP & Chief Commercial Officer | SELL | 324 | $9.50 | $3K |
| Mar 2, 26 | Kristin AbateChief Accounting Officer | SELL | 559 | $9.41 | $5K |
| Mar 2, 26 | Sohanya Roshan ChengEVP & Chief Commercial Officer | SELL | 4.6K | $9.41 | $43K |
| Mar 2, 26 | Michael ManoEVP, CLO&Secretary | SELL | 3.5K | $9.41 | $33K |
| Mar 2, 26 | Richard A. PaulsonPresident and CEO | SELL | 12.4K | $9.41 | $116K |
| Mar 2, 26 | Stuart PoultonEVP, Chief Development Officer | SELL | 5.1K | $9.41 | $48K |
| Mar 2, 26 | Reshma RangwalaEVP & Chief Medical Officer | SELL | 5.1K | $9.41 | $48K |
| Feb 17, 26 | Stuart PoultonEVP, Chief Development Officer | SELL | 378 | $8.63 | $3K |
| Feb 3, 26 | Lori MacomberEVP, CFO & Treasurer | SELL | 1.6K | $6.30 | $10K |
| Jan 28, 26 | Kristin AbateChief Accounting Officer | SELL | 50 | $7.03 | $352 |
| Jan 21, 26 | Kristin AbateChief Accounting Officer | SELL | 265 | $5.96 | $2K |
| Oct 1, 25 | Kristin AbateChief Accounting Officer | SELL | 362 | $6.30 | $2K |
| Sep 15, 25 | Kristin AbateChief Accounting Officer | SELL | 23 | $6.43 | $148 |
| Sep 15, 25 | Sohanya Roshan ChengEVP & Chief Commercial Officer | SELL | 325 | $6.43 | $2K |
| Sep 15, 25 | Michael ManoSVP, General Counsel&Secretary | SELL | 234 | $6.43 | $2K |
| Sep 15, 25 | Richard A. PaulsonPresident and CEO | SELL | 1.3K | $6.43 | $8K |
| Sep 15, 25 | Stuart PoultonEVP, Chief Development Officer | SELL | 401 | $6.43 | $3K |
| Sep 15, 25 | Reshma RangwalaEVP & Chief Medical Officer | SELL | 408 | $6.43 | $3K |
| Sep 3, 25 | Kristin AbateChief Accounting Officer | SELL | 12 | $6.78 | $81 |
| Jul 29, 25 | Stuart PoultonEVP, Chief Development Officer | SELL | 191 | $4.37 | $835 |
| Jul 22, 25 | Kristin AbateChief Accounting Officer | SELL | 238 | $4.00 | $952 |
| May 6, 25 | Richard A. PaulsonPresident and CEO | SELL | 236 | $7.12 | $2K |
| Apr 23, 25 | Reshma RangwalaEVP & Chief Medical Officer | SELL | 419 | $6.17 | $3K |
| Apr 4, 25 | Richard A. PaulsonPresident and CEO | SELL | 245 | $3.74 | $916 |
| Mar 4, 25 | Kristin AbateChief Accounting Officer | SELL | 571 | $6.29 | $4K |
| Mar 4, 25 | Sohanya Roshan ChengEVP & Chief Commercial Officer | SELL | 3.4K | $6.29 | $22K |
| Mar 4, 25 | Michael ManoSVP, General Counsel&Secretary | SELL | 2.8K | $6.29 | $18K |
| Mar 4, 25 | Richard A. PaulsonPresident and CEO | SELL | 11.7K | $6.29 | $74K |
| Mar 4, 25 | Stuart PoultonEVP, Chief Development Officer | SELL | 3.5K | $6.29 | $22K |
| Mar 4, 25 | Reshma RangwalaEVP & Chief Medical Officer | SELL | 3.6K | $6.29 | $23K |
| Feb 18, 25 | Stuart PoultonEVP, Chief Development Officer | SELL | 5.9K | $0.63 | $4K |
| Feb 4, 25 | Richard A. PaulsonPresident and CEO | SELL | 4.1K | $0.65 | $3K |
| Jan 6, 25 | Richard A. PaulsonPresident and CEO | SELL | 4.1K | $0.78 | $3K |
| Dec 4, 24 | Richard A. PaulsonPresident and CEO | SELL | 3.6K | $0.81 | $3K |
| Nov 5, 24 | Richard A. PaulsonPresident and CEO | SELL | 3.7K | $0.91 | $3K |
| Oct 4, 24 | Richard A. PaulsonPresident and CEO | SELL | 3.6K | $0.88 | $3K |
| Sep 4, 24 | Sohanya Roshan ChengEVP & Chief Commercial Officer | SELL | 5.4K | $0.72 | $4K |
| Sep 4, 24 | Michael ManoSVP, General Counsel&Secretary | SELL | 4.0K | $0.72 | $3K |
| Sep 4, 24 | Michael MasonEVP, CFO & Treasurer | SELL | 7.0K | $0.72 | $5K |
| Sep 4, 24 | Richard A. PaulsonPresident and CEO | SELL | 3.7K | $0.72 | $3K |
| Aug 6, 24 | Richard A. PaulsonPresident and CEO | SELL | 3.6K | $0.93 | $3K |
| Jul 30, 24 | Stuart PoultonEVP, Chief Development Officer | SELL | 2.9K | $1.06 | $3K |
| Jul 5, 24 | Richard A. PaulsonPresident and CEO | SELL | 3.6K | $0.85 | $3K |
| Jun 7, 24 | Deepika PakianathanDirector | SELL | 229.3K | $0.95 | $218K |
| Jun 6, 24 | Deepika PakianathanDirector | SELL | 117.3K | $0.98 | $115K |
| Jun 5, 24 | Deepika PakianathanDirector | SELL | 463.5K | $0.96 | $445K |
| Jun 4, 24 | Michael MasonEVP, CFO & Treasurer | SELL | 652 | $0.99 | $645 |
| Jun 4, 24 | Richard A. PaulsonPresident and CEO | SELL | 3.6K | $0.99 | $4K |
| Jun 4, 24 | Deepika PakianathanDirector | SELL | 337.7K | $0.95 | $321K |
Over the past 12 months, insiders at Karyopharm Therapeutics Inc. filed 0 open-market purchases worth $0 and 21 sales worth $333K on KPTI, which makes them net sellers over the period. The most recent Form 4 was filed on May 14, 26.
7 different insiders at Karyopharm Therapeutics Inc. filed open-market SEC Form 4 transactions on KPTI over the last 12 months.
InsiderTape plots every KPTI insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Karyopharm Therapeutics Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →